Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of “Buy” by Brokerages

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, two have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $28.00.

A number of equities research analysts have recently issued reports on TBPH shares. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. HC Wainwright lifted their target price on shares of Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. B. Riley started coverage on Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price on the stock. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. Finally, Wall Street Zen raised Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 23rd.

Theravance Biopharma Stock Up 1.8%

Shares of Theravance Biopharma stock opened at $20.31 on Wednesday. The firm has a market cap of $1.03 billion, a PE ratio of 35.63 and a beta of 0.14. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $20.33. The business’s fifty day simple moving average is $15.51 and its 200-day simple moving average is $13.02.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%.The firm had revenue of $19.99 million during the quarter, compared to the consensus estimate of $19.89 million. As a group, equities analysts expect that Theravance Biopharma will post -1.09 earnings per share for the current year.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC boosted its position in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 4,662 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in Theravance Biopharma in the third quarter valued at about $149,000. Caitong International Asset Management Co. Ltd grew its position in Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,411 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Theravance Biopharma by 100.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 40,538 shares of the biopharmaceutical company’s stock worth $592,000 after purchasing an additional 20,364 shares during the last quarter. Finally, PharVision Advisers LLC bought a new stake in shares of Theravance Biopharma during the 3rd quarter valued at about $157,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.